The prevalence of thyroid autoimmunity is high in patients with chronic idi
opathic urticaria (CIU), but in few selected patients the possible clinical
benefit of levothyroxine sodium or antithyroid drugs has been studied. The
objective of the present study was to confirm the prevalence of antithyroi
d antibodies in patients with CIU and to investigate the clinical response
to levothyroxine sodium or methimazole. Antithyroglobulin and antiperoxidas
e antibodies were measured in 170 consecutive patients with CIU. Twenty-fiv
e (14.7%) had an antithyroglobulin or antiperoxidase antibody levels >180 I
U/ml and all but three were women. Twenty patients with CIU and thyroid aut
oimmunity were treated with levothyroxine sodium if hypothyroidism or norma
l thyroid function were present (18 patients) and with methimazole if hyper
thyroidism was detected (two patients). Clinical response was evaluated by
a clinical score. Autologous serum skin test before treatment was performed
in 18 patients with thyroid autoantibodies. Urticaria resolved rapidly in
two patients with Graves' disease. The clinical response of urticaria to le
vothyroxine sodium treatment was good in 15 patients and partial in two, wh
ereas only one patient showed no improvement in clinical score (p <0.0005).
No changes in the antithyroglobulin or antiperoxidase levels were detected
Five patients reported adverse effects. The autologous serum skin test was
positive in 10 patients and negative in eight. After successful treatment
the test was repeated in six patients, proving negative in four and signifi
cantly diminished in two. We concluded that patients with CIU and thyroid a
utoimmunity benefit from treatment with levothyroxine sodium or antithyroid
drugs. Antithyroid antibodies and positive autologous serum skin test in t
hese patients could be markers of autoimmune disease with several target or
gans.